%0 Journal Article
%A Catanzaro, Giuseppina
%A Besharat, Zein Mersini
%A Carai, Andrea
%A Jäger, Natalie
%A Splendiani, Elena
%A Colin, Carole
%A Po, Agnese
%A Chiacchiarini, Martina
%A Citarella, Anna
%A Gianno, Francesca
%A Cacchione, Antonella
%A Miele, Evelina
%A Diomedi Camassei, Francesca
%A Gessi, Marco
%A Massimi, Luca
%A Locatelli, Franco
%A Jones, David
%A Figarella-Branger, Dominique
%A Pfister, Stefan
%A Mastronuzzi, Angela
%A Giangaspero, Felice
%A Ferretti, Elisabetta
%T MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression.
%J Biomarker Research
%V 10
%N 1
%@ 2050-7771
%C London
%I Biomed Central
%M DKFZ-2022-01282
%P 44
%D 2022
%X Pediatric low-grade gliomas (pLGGs), particularly incompletely resected supratentorial tumours, can undergo progression after surgery. However to date, there are no predictive biomarkers for progression. Here, we aimed to identify pLGG-specific microRNA signatures and evaluate their value as a prognostic tool.We identified and validated supratentorial incompletey resected pLGG-specific microRNAs in independent cohorts from four European Pediatric Neuro-Oncology Centres.These microRNAs demonstrated high accuracy in differentiating patients with or without progression. Specifically, incompletely resected supratentorial pLGGs with disease progression showed significantly higher miR-1248 combined with lower miR-376a-3p and miR-888-5p levels than tumours without progression. A significant (p < 0.001) prognostic performance for miR-1248 was reported with an area under the curve (AUC) of 1.00. We also highlighted a critical oncogenic role for miR-1248 in gliomas tumours. Indeed, high miR-1248 levels maintain low its validated target genes (CDKN1A (p21)/FRK/SPOP/VHL/MTAP) and consequently sustain the activation of oncogenic pathways.Altogether, we provide a novel molecular biomarker able to successfully identify pLGG patients associated with disease progression that could support the clinicians in the decision-making strategy, advancing personalized medicine.
%K Pediatric low-grade gliomas (Other)
%K Personalized medicine (Other)
%K Prognostic biomarker (Other)
%K Risk stratification (Other)
%K Tumour progression (Other)
%K miR-1248 (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35715818
%R 10.1186/s40364-022-00389-x
%U https://inrepo02.dkfz.de/record/180368